Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability

James D. Berry, Sabrina Paganoni, Nazem Atassi, Eric A. Macklin, Namita Goyal, Michael Rivner, Ericka Simpson, Stanley Appel, Daniela L. Grasso, Nicte I. Mejia, Farrah Mateen, Alan Gill, Fernando Vieira, Valerie Tassinari, Steven Perrin

Research output: Contribution to journalArticle

13 Scopus citations

Fingerprint Dive into the research topics of 'Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability'. Together they form a unique fingerprint.

Medicine & Life Sciences